A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Human Immunodeficiency Virus
Test CodeHIV
Alias/See Also
aHIV, anti-HIV Type1, anti-HIV Type2
CPT Codes
86703
Includes
anti-HIV Type 1, Anti-HIV Type 2
Preferred Specimen
Serum (gold or red top tube)
Minimum Volume
1.0 mL
Transport Container
Serum (gold or red top) Tube
Transport Temperature
Room Temperature, Refrigration or Freezing
Specimen Stability
Room Temperature - 8 hours; Refrigerated - 48 hours; Frozen - 1 month
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Turbidity, Quantity Not Sufficient, IV contamination
Methodology
Chemiluminescence
Setup Schedule
Daily upon receipt
Report Available
Upon completion of analysis
Limitations
A negative test result does not exclude the possibility of exposure to or infection with HIV. Levels of HIV antibodies may be undetectable in the early stages of infection. This test has not been validated for use with specimens from individuals less than 2 years of age. Samples with Total Protein > 9 g/dL amy give falsely reactive results. A person who has antibodies to HIV-1 or HIV-2 is presumed to be infected with the virus, except for individuals who have participated in an HIV vaccine study, who may develop antibodies to the vaccine and may or may not be infected with HIV. Clinical correlation is indicated with appropriate counseling, medical evaluation and possibly additional testing to decide whether a diagnosis of HIV infection is accurate.
Reference Range
Interpretation:
Non-Reactive: Specimen is negative for anti-HIV-1 and anti-HIV-2. A non-reactive test result does not exclude the possibility of exposure to or infection with HIV. Levels of HIV antibodies may be undetectable in the early stages of infection.
Reactive - Specimen is reactive for anti-HIV-1 and/or anti-HIV-2.
All Reactive specimens will be confirmed by Molecular testing methods.
Clinical Significance
In conjunction with other serological evidence and clinical information, anti-HIV1/2 may be used as an aid in the diagnosis of infection with HIV-1 and/or HIV-2 in persons with signs or symptoms, or at risk for, HIV.